AVNS

Company Overview — What Does AVANOS MEDICAL, INC. Do?

Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia. AVANOS MEDICAL, INC. (AVNS) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Joseph F. Woody and employs approximately 4,040 people, headquartered in Dallas, Georgia. With a market capitalization of $655M, AVNS is one of the notable companies in the Healthcare sector.

AVANOS MEDICAL, INC. (AVNS) Stock Rating — Hold (April 2026)

As of April 2026, AVANOS MEDICAL, INC. receives a Hold rating with a composite score of 39.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.AVNS ranks #1,497 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AVANOS MEDICAL, INC. ranks #131 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AVNS Stock Price and 52-Week Range

AVANOS MEDICAL, INC. (AVNS) currently trades at $14.18. The stock gained $0.09 (0.6%) in the most recent trading session. The 52-week high for AVNS is $15.68, which means the stock is currently trading -9.6% from its annual peak. The 52-week low is $9.30, putting the stock 52.4% above its annual trough. Recent trading volume was 312K shares, suggesting relatively thin trading activity.

Is AVNS Overvalued or Undervalued? — Valuation Analysis

AVANOS MEDICAL, INC. (AVNS) carries a value factor score of 37/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.82x, versus the sector average of 2.75x. The price-to-sales ratio is 0.92x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, AVNS trades at 1825.23x EV/EBITDA, versus 6.34x for the sector.

At current multiples, AVANOS MEDICAL, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

AVANOS MEDICAL, INC. Profitability — ROE, Margins, and Quality Score

AVANOS MEDICAL, INC. (AVNS) earns a quality factor score of 36/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -8.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -6.3% versus the sector average of -33.1%.

On a margin basis, AVANOS MEDICAL, INC. reports gross margins of 52.3%, compared to 71.5% for the sector. The operating margin is -7.3% (sector: -66.1%). Net profit margin stands at -9.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 3.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AVNS Debt, Balance Sheet, and Financial Health

AVANOS MEDICAL, INC. has a debt-to-equity ratio of 12.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.38x, indicating strong short-term liquidity. Total debt on the balance sheet is $93M. Cash and equivalents stand at $71M.

AVNS has a beta of 0.85, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for AVANOS MEDICAL, INC. is 65/100, reflecting average volatility within the normal range for its sector.

AVANOS MEDICAL, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, AVANOS MEDICAL, INC. reported revenue of $691M and earnings per share (EPS) of $-0.03. Net income for the quarter was $-67M. Gross margin was 52.3%. Operating income came in at $-52M.

In Q3 2025, AVANOS MEDICAL, INC. reported revenue of $178M and earnings per share (EPS) of $-0.03. Net income for the quarter was $-1M. Gross margin was 48.4%. Revenue grew 4.3% year-over-year compared to Q3 2024. Operating income came in at $100,000.

In Q2 2025, AVANOS MEDICAL, INC. reported revenue of $175M and earnings per share (EPS) of $-1.66. Net income for the quarter was $-77M. Gross margin was 52.6%. Revenue grew 1.9% year-over-year compared to Q2 2024. Operating income came in at $-75M.

In Q1 2025, AVANOS MEDICAL, INC. reported revenue of $168M and earnings per share (EPS) of $0.14. Net income for the quarter was $7M. Gross margin was 53.6%. Revenue grew 0.8% year-over-year compared to Q1 2024. Operating income came in at $10M.

Over the past 8 quarters, AVANOS MEDICAL, INC. has demonstrated a growth trajectory, with revenue expanding from $166M to $691M. Investors analyzing AVNS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AVNS Dividend Yield and Income Analysis

AVANOS MEDICAL, INC. (AVNS) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AVNS Momentum and Technical Analysis Profile

AVANOS MEDICAL, INC. (AVNS) has a momentum factor score of 49/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 32/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 16/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

AVNS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AVANOS MEDICAL, INC. (AVNS) ranks #131 out of 838 stocks based on the Blank Capital composite score. This places AVNS in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AVNS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AVNS vs S&P 500 (SPY) comparison to assess how AVANOS MEDICAL, INC. stacks up against the broader market across all factor dimensions.

AVNS Next Earnings Date

No upcoming earnings date has been announced for AVANOS MEDICAL, INC. (AVNS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AVNS? — Investment Thesis Summary

AVANOS MEDICAL, INC. presents a balanced picture with arguments on both sides. The quality score of 36/100 flags below-average profitability. The value score of 37/100 indicates premium valuation. Low volatility (stability score 65/100) reduces downside risk.

In summary, AVANOS MEDICAL, INC. (AVNS) earns a Hold rating with a composite score of 39.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AVNS stock.

Related Resources for AVNS Investors

Explore more research and tools: AVNS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AVNS head-to-head with peers: AVNS vs AZN, AVNS vs SLGL, AVNS vs VMD.